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SUMMARY
Despite its clinical significance, the mechanisms of joint morphogenesis are still elusive. Here, we
show by combining laser-capture microdissection for RNA sampling with microarray analysis,
that the setting in which joint-forming interzone cells develop is distinct from adjacent growth
plate chondrocytes and is characterized by down-regulation of chemokines, such as monocyte-
chemoattractant protein-5 (MCP-5). Using in-vivo, ex-vivo and in-vitro approaches, we showed
that low levels of interzone-MCP-5 are essential for joint formation and contribute to proper
growth plate organization. Mice lacking the TGF-β-type-II-receptor (TβRII) in their limbs
(Tgfbr2Prx1KO), which lack joint development and fail chondrocyte hypertrophy, showed up-
regulation of interzone-MCP-5. In-vivo and ex-vivo blockade of the sole MCP-5 receptor, CCR2,
in Tgfbr2Prx1KO led to rescue of joint formation and growth plate maturation; while in control
mice determined an acceleration of endochondral growth plate mineralization. Taken together, we
characterized the TβRII/MCP-5 axis as an essential crossroad for joint development and
endochondral growth.
INTRODUCTION
Synovial joints, which separate adjacent skeletal elements from each other, are important
signaling centers that control chondrocyte maturation within the endochondral template
(Francis-West et al., 1999). Although their evolutionary, physiological and clinical
significance there is limited information on the mechanisms and signaling molecules that
lead to joint morphogenesis. Morphologically, the position of each future joint is first
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delimited by the interzone development, consisting of a region of compact mesenchymal
cells between two adjacent growth plates. Interzone cells adopt a nonchondrogenic
phenotype, as indicated by the loss of chondrogenic markers such as Sox-9 and Collagen 2,
and instead express new sets of genes including Gdf5, Wnt9a and Wnt4 (Hartmann and
Tabin, 2001; Pacifici et al., 2006; Storm et al., 1994). There is limited information of the
entry mechanism leading to interzone initiation, the gene expression environment in which
interzone cells emerge and distinct themselves from adjacent growth plate chondrocytes and
how joint morphogenic molecules are interconnected within the joint and with the other
skeletogenic components of the developing bone (Dowthwaite et al., 2004; Koyama et al.,
2008). Articular cartilage is avascular, and this limits its reparative capacity such that
arthritis is the single largest cause of disability in the adult population (CDC, January
12,2007). A greater understanding of joint formation can provide critical insight on the
pathogenesis of joint degeneration and to develop novel reparative strategies to treat
arthritis.
In adult articular cartilage, inflammatory cytokines critically target the joints causing their
degeneration. Monocyte chemoattractant protein-5 (MCP-5, a.k.a. CCL12) belongs to the
family of CC chemokines and is the structural and functional homologue of human MCP-1
(Sarafi et al., 1997). MCP-5 binds exclusively to CC-chemokine receptor 2 (CCR2) that is
the primary receptor for human MCP-1 (Sarafi et al., 1997; Tsou et al., 2007). MCP-5, as
well as MCP-1, is a potent chemoattractant for circulating monocytes to sites of
inflammation where they become cytokine-secreting macrophages (Charo and Ransohoff,
2006; Mack et al., 2001; Sarafi et al., 1997). CCR-2 has received major clinical attention in
arthritis, as it has been regarded as a therapeutic target to be blocked (Charo and Ransohoff,
2006; Quinones et al., 2005). An increased number of CCR2+ cells is found in the inflamed
joints of patients with different forms of arthritis (Nanki et al., 2001; Ruth et al., 2001).
CCR-2 is also increased in rodent models of arthritis, although levels change during the
different phases of the disease (Szekanecz et al., 2000; Thornton et al., 1999). In addition,
increased levels of MCP-1 have been found in patients with osteoarthritis (OA) and
rheumatoid arthritis (RA) (De Benedetti et al., 1999; Hayashida et al., 2001). These lines of
evidence have led to the development of several antagonists of and antibodies against
CCR-2 and MCP-1 (Feria and Diaz-Gonzalez, 2006; Quinones et al., 2005). While the role
of inflammatory cytokines such as MCP-5 in the arthritic process appears indisputable, their
role in joint development has never been evaluated. A finding of cytokine involvement in
joint formation would determine a shift in our current view of joint cells not anymore as
passive victims of the disruptive force of cytokines but as active participants in maintaining
under control the cytokine effects and therefore joint integrity.
Genetic manipulation of the TGF-β system has revealed critical roles in both joint
development and skeletogenesis (Ito et al., 2003; Serra et al., 1997; Spagnoli et al., 2007).
TGF-β type II receptor (TβRII) is the only TβR that is capable of binding all the TGF-β
isoforms resulting in functional signaling. Mice that are germline-null for the Tgfbr2 exhibit
early embryonic lethality making it impossible to evaluate the role of TGF-β signaling in
skeletogenesis (Oshima et al., 1996). In previous studies, by generating the Tgfbr2-GFP-β-
GEO-BAC imaging (β-Gal and GFP) reporter mouse, we showed that TβRII is highly and
specifically expressed in developing joints (Spagnoli et al., 2007). Furthermore, by
generating a mouse in which the TβRII signaling is conditionally inactivated in limb buds
starting at E9.5 (Tgfbr2Prx1KO), we demonstrated that the lack of TGF-β signaling was
associated with complete absence of interphalangeal joints as well as with impaired growth
plate development (Spagnoli et al., 2007).
In this study, we have found that the joint interzone emerges within the developing limb
mesenchyme expressing a gene-expression pattern that is distinct from the adjacent
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developing growth plate chondrocytes and is characterized by a down-regulation of
chemokines, in particular MCP-5. MCP-5 down-regulation is impaired in the Tgfbr2Prx1KO
mutants that lack joint development. By using in-vivo, ex-vivo, and in-vitro approaches we
demonstrated that an aberrant presence of MCP-5 within the developing limb is sufficient to
impair joint formation and within the developing growth plate, to alter the rate of
progression of pre-hypertrophic chondrocytes to hypertrophy and mineralization. The in-
vivo and ex-vivo blockade of the CCR2 signaling (MCP-5 sole receptor) in Tgfbr2Prx1KO
mice, led to a rescue of their phenotype, restoring joint cavitation and expression of joint
morphogenic genes while promoting the proper growth plate maturation. Our findings by
demonstrating the essential role of the TβRII/MCP-5 axis in the interplay between the
developing articular cartilage and the growth plate, provide evidence of a function for a
cytokine during skeletal development and open a novel prospective for evaluating and
therapeutically targeting the TβRII/MCP-5 axis in OA.
RESULTS
MCP-5 is differentially expressed in interzone cells and adjacent chondrocytes, and such
expression pattern is impaired in Tgfbr2Prx1KO mice
In order to investigate the distinct gene expression profile where interzone cells emerge
between the forming growth plates, we obtained RNA samples from E14.5 interzone cells
and adjacent growth plate chondrocytes of Tgfr2flox/flox (normal control, NC) and
Tgfbr2Prx1KO digits using laser capturing microdissection (LCM). Figure 1A depicts the
regions that were subjected to LCM; in the Tgfbr2Prx1KO, the presumptive interzone was
identified as a bending between two growth plates. After verifying RNA integrity (see
Methods), specimens were subjected to microarray analysis. Normalized data were
expressed as fold changes of a candidate gene in the interzone sample compared to the
expression found in the sample from adjacent growth plate chondrocytes. As initial
validation step, we examined the expression of genes that we had previously found to be
specifically up-regulated in the interzone compared to adjacent growth plate chondrocytes
by in situ hybridization (ISH), immunohistochemistry (IHC) and RT-PCR (Spagnoli et al.,
2007). Microarray analysis confirmed that in the NC interzone, Jagged1, Tgfbr2, Pdgfrb and
Wnt9a were up-regulated respectively 243.9 fold, 12.29 fold, 66.1 fold and 3.43 fold,
compared to adjacent growth plate chondrocytes, while such regulation was impaired in the
Tgfbr2Prx1KO (respectively Jagged1, 1.32 fold; Tgfbr2, 1.27 fold; Pdgfrb, 0.97 fold; Wnt9a,
0.99 fold). Next, we performed a pathway analysis using PANTHER (Protein Analysis
Through Evolutionary Relationships) Classification System (Celera) to identify functional
categories in the joint-forming interzone cells compared to adjacent growth plate
chondrocytes. The PANTHER is a unique resource that classifies genes into canonical
pathways to predict function (Thomas et al., 2003). As shown in Figure 1B, we found that in
the NC interzone cells the “Inflammation mediated by chemokine and cytokine signaling
pathway” was extensively down-regulated compared to adjacent chondrocytes; of a total of
337 genes classified in this pathway, 227 were down-regulated more than 2 fold. Within the
genes down-regulated, Mcp-5 was down-regulated ~800 fold and its unique receptor, Ccr2,
~11 fold, while such differential expression was impaired in the Tgfbr2Prx1KO (Figure 1C).
As further validation of the microarrays data, we performed qRT-PCR on RNA samples
obtained by LCM from interzone and adjacent growth plate chondrocytes from E14.5 NC
and Tgfbr2Prx1KO as well as ISH and IHC analysis on E14.5 limbs either from NC or
Tgfbr2Prx1KO mice. As shown in Figure 1D, qRT-PCR analyses showed that the expression
of Mcp-5 in NC interzone was more than 900 fold lower than its expression in NC
chondrocytes. In contrast, the Tgfbr2Prx1KO presumptive interzone expressed levels of
MCP-5 that were higher than the NC interzone (more than 130 fold) and were not
significantly different from levels found in Tgfbr2Prx1KO growth plate chondrocytes. ISH
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and IHC studies corroborated these findings (Figure 1E and 1F). Our data show that the joint
interzone cells demonstrate a down-regulation of MCP-5 mRNA and protein levels
compared to adjacent developing growth plate cells and that such down-regulation is
abolished in Tgfbr2Prx1KO developing limbs.
To determine MCP-5 expression through joint development we extended IHC analyses of
MCP-5 in E12.5; E13.5, E14.5; E16.5 and E18.5 NC (Figure S1). We found that MCP-5
expression started at E13.5 within the developing digits. By E14.5, MCP-5 expression was
restricted to the growth plate chondrocytes while was not expressed in the joint at any stage.
Aberrant release of MCP-5 within normal developing limbs alters joint formation, while
blockade of CCR2 signaling is able to rescue the joint phenotype of Tgfbr2Prx1KO mutants
In order to determine a role for the restricted levels of MCP-5 within the interzone, we used
an ex-vivo approach in which hydrophobically-modified glycol chitosan (HGC)-
nanoparticles loaded with MCP-5 protein were microinjected in the interzone of E14.5 WT
dissected autopods (Figure 2A) to lead to an aberrant sustained release of MCP-5 within the
developing joints. HGC-nanoparticles are biocompatible and non immunogenic and consist
in hydrophilic shells and hydrophobic cores that bind proteins (Hirano, 1999; Li et al.,
2010). We have developed a micro-injection unit that allows for precise injection
localization and volume accuracy delivery (nanoliters) within distinct regions of developing
autopods and reported that proteins are slowly released from HGC without diffusing (~90%
in 48h), are biologically active and HGC do not interfere with skeletogenesis, including joint
development (Li et al., 2010). Based on these pharmacokinetics studies, HGC-MCP-5
(delivering 1.5 ng of MCP-5 protein) was injected at the joint sites of E14.5 dissected
autopods that were cultured for 2 days; un-injected joints from the same embryo were used
as control (Figure 2A). IHC for MCP-5 showed that protein was sustainably delivered (after
48 h) within the interzone; Figure 2A shows that MCP-5 was detectable in the
interphalangeal joint sections from the 2nd digit implanted with HCG-MCP-5, while it was
undetectable in the uninjected control joint interzone of the 5th digit, in which endogenous
MCP-5 was restricted to the adjacent growth plate chondrocytes. Compared to un-injected
control, the aberrant sustained delivery of MCP-5 from HCG-MCP-5 implant within the
developing interzone abolished Gdf5 expression and altered the interzone Collagen2
expression pattern. In fact, the interzone of implanted HCG-MCP-5 digits lost the
characteristic chondrocyte segmentation and Collagen2 expressing cells appeared
continuously distributed along the entire digit (Figure 2B). Increasing doses (0.75 to 1.5 ng)
of implanted MCP-5 within the interzone resulted in gradual impairing of Gdf5 and
Collagen2 patterns. Similar effects on Gdf5 and Collagen2 expressions were found among
the 1.5 ng to the 6 ng doses, therefore 1.5 ng was used in all further experiments (data not
shown). At least 3 embryos were implanted with each dose and at least 3 sections from each
embryo were subjected to ISH analyses.
To determine whether the blockade of CCR2 (the sole MCP5 receptor) would restore
interphalangeal joint formation in Tgfbr2Prx1KO developing limbs, we used ex-vivo as wells
as in-vivo approaches. We first evaluated CCR2 expression by IHC at different joint
developmental time points (E12.5; E13.5, E14.5 and E18.5). CCR-2 expression was first
detected within the developing digit at E13.5 and by E14.5 expression was found within the
developing interzone and growth plates. This expression pattern was maintained up to E18.5
(Figure S2). To block the CCR2 signaling, we used the HCG-based ex-vivo autopod culture
technique; in particular, we implanted HCG-MC-21 nanoparticles (delivering 1.5ng of
MC-21 antibody) in the presumptive interzone of E14.5 Tgfbr2Prx1KO mutants as well as
NC littermates. The MC-21 is an anti-mouse CCR-2 monoclonal antibody that has been
shown to block the murine CCR-2 with high affinity in vivo as well as in vitro (Bruhl et al.,
2004; Mack et al., 2001). Histological and ISH studies demonstrated that blockade of
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MCP-5 signaling was able to restore the joint cavitation and Gdf5 expression abnormally
missing in the mutants. In addition, while in mutant limbs Sox-9 and Collagen2 expressing
cells were continuously distributed along the digit, in MC-21-implanted mutants they
appeared to be restricted to the growth plate chondrocytes, adopting an expression pattern
that was similar to controls (Figure 3A). For the in-vivo studies, pregnant females
potentially carrying Tgfbr2Prx1KO embryos were treated orally with 4mg/Kg/day of
RS-504393 (a selective CCR2 inhibitor) starting at E11.5 and until either E14.5 or E18.5,
when mice were sacrificed. The two time points allowed to determine the need of CCR-2
signaling in joint formation (E14.5) as well as its persistent effect at a later stage (E18.5). As
shown in Figure 3B, blockade of MCP-5 signaling in Tgfbr2Prx1KO embryos in-vivo was
sufficient to restore Gdf5 expression and Collagen2 segmentation in E14.5 embryos. These
effects were maintained in E18.5 Tgfbr2Prx1KO embryos resulting in a well-defined joint
space in between the growth plates (Figure 3C). Blockade of MCP-5 signaling in NC limbs,
both ex-vivo and in-vivo, did not affect joint maturation and chondrocyte segmentation
(Figure 3A–B). Our results indicate that a down-regulation of MCP-5 in developing
interzone is needed for proper joint formation, Gdf5 and Collagen2 expressions and reveal
the critical role for TGF-β signaling in controlling restrained levels of MCP-5 within the
developing joints.
MCP-5 acts as a chondrogenic factor on isolated interzone cells. TGF-β inhibits MCP-5
expression on isolated TβRII+ cells
We have recently reported that within the interphalangeal joints TβRII expressing cells
localize in specific niches such as the ventral and dorsal sites of the interzone (Figure S3) (T.
Li, 2011). Reasoning that TβRII expressing cells control the developing environment of the
interzone through paracrine and autocrine mechanisms, we relied on the microarray analysis
as a source to identify additional genes that encode for membrane-associated proteins that
are exclusively expressed in the interzone of NC but not in Tgfbr2Prx1KO mice (i.e. Jagged1
and Pdgfrb), to isolate interzone cells from E14.5 autopod mesenchyme. An
immunomagnetic selection system was used to isolate Jagged1, TβRII and PDGFRβ
positive (Jag+/TβRII+/PDGFR+) cells that accounted for ~1% of the total (~30×106 total
cells from 30 embryos). mRNA was collected immediately after cell separation from the
Jag+/TβRII+/PDGFR+ cell fraction and subjected to RT-PCR. As shown in Figure 4A, Jag+/
TβRII+/PDGFR+ cells expressed key joint markers, such as Gdf5, Wnt9a, Sulf1 and
Collagen1. With the purpose of understanding the effect of MCP-5 on interzone cells, we
cultured the isolated Jag+/TβRII+/PDGFR+ fraction in micromass and treated them with or
without MCP-5 (20 ng/ml) for 3 days. MCP-5 induced a chondrogenic-like phenotype in the
cells that condensate in typical chondrogenic nodules (Figure 4B). In addition, MCP-5
treatment determined a marked decrease in the expressions of Gdf5, Wnt9a and Sulf1, while
increasing Collagen2, compared with untreated cells (Figure 4C). These in-vitro data
support our ex-vivo and in-vivo findings indicating that a down-regulation of MCP-5 is
needed in interzone cells to allow a correct expression of key joint markers. The
chondrogenic action of MCP-5 can be the consequence of several mechanisms ranging from
proliferation to regulation of transcription of chondrogenic gene markers. Future
investigations will be needed to dissect such mechanisms.
Hypothesizing that only the TGF-β signaling regulates MCP-5 expression we exclusively
isolated TβRII expressing cells (TβRII+) from E14.5 limb mesenchyme of Tgfbr2-GFP-β-
GEO-BAC transgenic mice. Tgfbr2-GFP-β-GEO-BAC mice contain both GFP and LacZ as
imaging reporters for Tgfbr2 expression (Spagnoli et al., 2007). TβRII+ cells were FACS
sorted using GFP as isolation marker and cultured in micromass for 18h with or without
TGF-β (20ng/ml). qRT-PCR analyses showed that TGF-β significantly decreased MCP-5
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expression compared to untreated controls (Figure 4D). These results support our hypothesis
that TGF-β is needed to down-regulate MCP-5 expression.
Aberrant release of MCP-5 within the developing joints of WT mice alters the growth plate
organization while blockade of CCR2 signaling in Tgfbr2Prx1KO mutants restores the
growth plate phenotype
Since lack of joint development in Tgfbr2Prx1KO mice was associated with selective
perturbative effects on the adjacent growth plate chondrogenesis with deregulated Ihh
expression and blockage of pre-hypertrophic to hypertrophic chondrocyte progression
(Spagnoli et al., 2007), we decided to investigate the contribution of MCP-5 to such
derangements. ISH studies of ex-vivo limb cultures injected with HGC-MCP-5 showed that
the aberrant release of MCP-5 within the interzone of WT mice impaired Ihh spatial
organization, producing a diffuse pattern of expression along the growth plate, and
significantly decreased Collagen10 expression by hypertrophic chondrocytes (Figure 5).
These results indicate that the aberrant presence of MCP-5 within the joint leads to a signal
from the joints toward the adjacent growth plate that controls the chondrocyte maturation. It
is important to remark that ex-vivo cultured limbs progress to chondrocyte maturation. As
depicted in Figure S4, histological and ISH analyses showed that E14.5 limbs cultured ex-
vivo for 2 days progress toward chondrocyte hypertrophy, as indicated by the increase in
Collagen10 expression when compared to E 14.5 uncultured limbs.
To analyze whether the elevated MCP-5 levels found in Tgfbr2Prx1KO mutants contributed
to the failure of hypertrophic chondrocyte maturation, we analyzed if blockade of MCP-5
signaling in the presumptive interzone of Tgfbr2Prx1KO by both ex-vivo and in-vivo
approaches, rescued the growth plate phenotype. Histological and ISH studies demonstrated
that both ex-vivo HGC-MC21 implant and in vivo RS-504383 treatment in Tgfbr2Prx1KO
embryos rescued the Ihh spatial organization and restored Collagen10 and Collagen1
expressions to levels similar to the NC (Figure 6A–6B). Notably, in the ex-vivo as wells as
the in-vivo studies, blockade of MCP-5 signaling in NC determined an increase in
Collagen10 and Collagen1 expressions and a reduction in size of the primary ossification
center that appeared to undergo to rapid mineralization (Figures 6A–B). These findings
point out that MCP-5 plays an additional role in the growth plate maturation that in this case
is independent from the TβRII signaling.
DISCUSSION
Our results demonstrate that within the joint interzone a down-regulation of MCP-5 is
critical to drive proper joint and endochondral development and that TβRII signaling is
needed in maintaining such down-regulation. Furthermore, we determined that the TβRII-
independent expression of MCP-5 within the growth plate plays a role in chondrocyte
maturation and hypertrophy. Taken together, these results lead us to propose the model
showed in Figure 7. In this model we propose that a crosstalk between the forming interzone
and the developing growth plate, mediated by MCP-5 through TβRII-dependent and TβRII-
independent mechanisms, is critical for proper joint and skeletal development. Our findings
represent a paradigm shift in the joint biology research field that presently perceives joints
as the passive victims of inflammatory cytokines that cause their degeneration. Instead, our
studies demonstrate that joints hold an active developmental mechanism that is operated by
the TβRII signaling to tightly regulate the expression of cytokines such as MCP-5 and such
mechanism is essential for joint morphogenesis.
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TβRII/MCP-5 axis in joint development
Though no one disputes that interzone is needed for joint formation, there is limited
information on the interzone joint-forming cell population and the role that these cells play
in the process remains far from clear. The formation of the interzone is specified by an
inductive signal in a restricted area of the chondrogenic blastema that leads to loss of
Collagen2 expressing cells while joint marker (i.e. GDF-5) expressing cells emerge and
segment the adjacent growth plates. It is unclear whether Collagen 2 expressing cells
undergo to a selection process (cell death) or whether their transcriptome becomes
programmed only toward joint marker expression (Khan et al., 2007). Combining LCM with
gene-profiling analyses, we found that the progenitor joint-forming interzone cells develop
in a setting that is distinct from the setting of the adjacent growth plate chondrocytes and
characterized by a down-regulation of specific cytokines/chemokines, such as MCP-5. Our
ex-vivo studies demonstrate that this differentially controlled expression of MCP-5 in the
interzone versus the adjacent chondrocytes is essential for the proper process of interzone
formation leading to expression of key joint markers (such as Gdf5), as well as the correct
segmentation of adjacent growth plates. Consistently, the aberrant release of MCP-5 within
the interzone interfered with its initiation and halted the segmentation process. Furthermore,
in our in-vitro experiments we demonstrated a direct effect of MCP-5 on isolated interzone
cells, characterized by a marked decrease in the expression of key joint markers (Gdf5,
Wnt9a and Sulf1) accompanied with a stimulation of Collagen 2 expression and emergence
of a chondrogenic phenotype. Our data support the hypothesis that interzone cells are
capable to be committed to either joint forming cells or chondrocytes and MCP-5 plays a
critical role in directing their differentiative program.
We have previously reported that the joints of Tgfbr2Prx1KO mutants appear to be arrested in
their development about the time when interzone starts to develop; differentiated
chondrocytes extend with a continuous pattern across the phalanges lacking interzone cell
condensation and Jagged-1, Noggin and Gdf-5 expressions (Spagnoli et al., 2007). In the
present study, we found that MCP-5 down-regulation was completely impaired in the
interzone of Tgfbr2Prx1KO mice indicating that the TβRII signaling is needed to control
MCP-5 expression and suggesting that the failure of the mutant’s joint formation may be
due to the aberrant expression of MCP-5. Our ex-vivo and in-vivo studies sustained this
hypothesis showing that in Tgfbr2Prx1KO mice, the inhibition of MCP-5 activity by blocking
its receptor CCR2 restored joint formation and in particular Gdf-5 expression and
chondrocyte segmentation. Furthermore, a direct inhibitory action of TGF-β on MCP-5
expression was found in our in-vitro studies by treating TβRII+ cells (isolated from limb bud
mesenchyme) with TGF-β. These findings classify MCP-5 as a key downstream mediator of
TβRII signaling in its critical role as a joint-forming initiator. We postulate that interzone
cells are programmed by the TβRII signaling to commit to joint forming cells by repressing
MCP-5/CCR2 signaling while halting their differentiative program to Collagen 2 expressing
chondrocytes.
MCP-5 its human homolog MCP-1 and its receptor CCR-2 have been largely studied in the
arthritic process. The current hypothesis is that those MCPs are produced and act primarily
through inflammatory cells (mostly monocytes) that are recruited within the arthritic joints
(Haringman and Tak, 2004; Tak, 2006). Although there are substantial pharmacological data
supporting a role for CCR2 antagonists in improving the course of experimental arthritis,
reports with CCR2 knock-out and anti-CCR2 blocking antibody (MC-21) have provided
contrasting results. In fact CCR2 knock-out mice are more susceptible to develop arthritis
and in experimental arthritis MC-21 treatment improved the disease when given at an early
stage while worsened when given later (Bruhl et al., 2004). Clinical studies using different
interventions to block the MCP5/CCR-2 axis in patients with RA have showed
disappointing results (Quinones et al., 2005). CCR2 is expressed in chondrocytes but its
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function is unknown (Borzi et al., 2000; Pulsatelli et al., 1999). Our data provide evidence
for a role of the MCP-5/CCR-2 system that targets directly the joint cells. Future studies will
be important to determine whether the TβRII signaling regulates MCP-5 expression to
maintain articular cartilage integrity in adulthood. In this respect, the OA/RA process could
be seen as the failure of an active cell joint population (TβRII cells) that is preserved
throughout life to maintain a controlled cytokine environment rather than the result of
passive joint cell degeneration due to the influx of inflammatory cells. The lack of CCR2 in
the knock-out mice and the timing of the blockage by the MC-21 antibody in the OA studies
may have perturbed the TβRII/MCP-5 equilibrium either in the wrong cells or at the wrong
time. Consistent with this hypothesis is our observation that TβRII expressing cells localize
in specific niches (T. Li, 2011).
TβRII/MCP-5 in endochondral cartilage development
It has been hypothesized that the developing joint acts as signaling center to control the
adjacent endochondral template development (Archer et al., 2003). Our ex-vivo studies
showed that release of MCP-5 within the interzone leads to an impairment of Ihh spatial
organization and to a decrease of Collagen10 expression. Notably, this phenotype coincided
with the one observed in the Tgfbr2Prx1KO mutants suggesting a role for MCP-5 in the
failure of the mutant’s chondrocyte progression to hypertrophy. This hypothesis was
corroborated by our ex-vivo and in-vivo experiments: blockade of MCP-5 signaling in
Tgfbr2Prx1KO mice rescued Ihh, Collagen10 and Collagen1 expression patterns. Taken
together, these results clearly indicate the need for TβRII signaling in maintaining low levels
of MCP-5 in the interzone and therefore to signal, through a still undefined factor, the
adjacent growth plate template maturation. Future studies are needed to identify such
factor(s); potential candidates could be members of WNT family. The interzone expresses
several members of the Wnt/β-catenin system that seem to be involved in joint formation
(Hartmann et al., 2000; Hartmann and Tabin, 2001; Luyten et al., 2009; Spater et al., 2006).
In addition, Wnt9a and β-catenin regulate Ihh expression (Spater et al., 2006). Since in
isolated interzone cells we found an inhibitory effect of MCP-5 on Wnt9a expression and
demonstrated a TβRII-dependent role for MCP-5 in regulating Ihh spatial organization in-
vivo, we speculate Wnt9a as the missing ring linking MCP-5 and Ihh expressions and
foresee future studies in this direction.
An outstanding question is what role, if any, does MCP-5 expressed by chondrocytes within
the growth plate play in the endochondral mineralization process? Our data contribute to
answer this question. We found that in normal limbs, the inhibition of MCP-5 activity within
the growth plate resulted in an increase of Collagen10 by hypertrophic chondrocytes and, at
later stages, Collagen1 in the ossification center. These findings indicate that, in addition to
its indirect action from the joints, MCP-5 within the growth plate affects the growth plate
maturation, inhibiting hypertrophy. Since the lack of TβRII signaling in the Tgfbr2Prx1KO
mutants does not seem to affect MCP-5 expression in the growth plate, it is likely that this
effect of MCP-5 is independent of TβRII signaling. Interestingly, blockade of MCP-5
activity in Tgfbr2Prx1KO mutants, did not lead to an increase in mineralization. One
explanation could be that in normal mice, differently from Tgfbr2Prx1KO mutants, blockade
of the MCP-5-dependent inhibitory action on chondrocyte maturation could be additive with
the MCP-TGF-β-dependent mechanism(s) promoting hypertrophy and ossification. As
expected, in control mice no joint derangement was found as consequence of MCP-5
inhibition, being MCP-5 already undetectable in normal joints and indicating that MCP-5
from the growth plate has not effect on joint development.
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A model for the TβRII/MCP-5 axis in joint and growth plate development
In Figure 7, we propose a dual role for MCP-5: it regulates cell commitment to either joint
forming cells or chondrocytes within the joints and blocks the progression to chondrocyte
hypertrophy and mineralization within the growth plate. These MCP-5 actions are TβRII-
dependent within the joints while TβRII-independent in the growth plate (Figure 7A).
Specifically, TβRII signaling, by blocking MCP-5 expression in the interzone, halts
Collagen2 expression, induces interzone specific markers (i.e. Gdf5) and signals to the
growth plate in favor of chondrocyte hypertrophy by proper Ihh expression. On the other
end, MCP-5 within the growth plate through a TβRII-independent mechanism inhibits
chondrocyte hypertrophy. The balance between these two opposite signals, by tightly
regulating the number of chondrocytes proceeding toward terminal differentiation, is
necessary for a proper endochondral ossification process.
The model in Figure 7B shows the TβRII contribution to the MCP-5 actions: in
Tgfbr2Prx1KO mutants, lack of the TβRII signaling leads to disregulated levels of interzone
MCP-5 that, in turn, blocks expression of interzone-specific markers (i.e. Gdf5), while
increasing Collagen2 expressing cells, with consequent accumulation of chondrocytes
within the joint region. In addition, MCP-5 up-regulation in interzone is accountable for the
impairement in Ihh spatial organization that alters the number of chondrocytes undergoing
hypertrophy and does not counteract the MCP-5-inhibitory effect coming from within the
growth plate. As consequence, there is an accumulation of disorganized pre-hypertrophic
chondrocytes throughout the growth plate. Blockade of MCP-5 in Tgfbr2Prx1KO mutants is
sufficient to rescue both their joint phenotype and chondrocyte maturation, indicating in
MCP-5 a key regulator for the TGF-β action.
EXPERIMENTAL PROCEDURES
Mouse strains
Tgfbr2Prx1KO mutants were generated as previously reported by crossing Tgfbr2flox/flox
homozygous females, defined as Normal Control (NC) in the manuscript, with males Prx-1-
Cre (provided by C. Tabin, Harvard University) (Spagnoli et al., 2007). In the Prx-1-Cre
mouse, the Prx-1 limb enhancer drives Cre recombinase expression in limb buds beginning
at E9.5 (Logan et al., 2002). Experiments were performed in mice that were C57BL/6 strain
for at least 10 generations. Tgfbr2-GFP-β-GEO-BAC mice were generated as previously
reported (Spagnoli et al., 2007).
For all timed pregnancies, noon of the day when evidence of a vaginal plug was found was
considered E0.5. All animal procedures were approved by the animal care committees of
Vanderbilt University and University of North Carolina at Chapel Hill.
LCM for RNA sampling and Microarray analysis
We obtained E14.5 autopods from two NC and two Tgfbr2Prx1KO littermate embryos.
Samples were frozen in OTC and cryosectioned (6µm), then processed with ethanol and
xylene, and subjected to LCM. To minimize RNA degradation, the process from sectioning
to shipment was performed in less than 20 minutes. We sequentially laser-captured cells in
the interzone and the adjacent growth plates from NC and Tgfbr2Prx1KO mutants (n=2). In
the Tgfbr2Prx1KO sections the presumptive interzone was identified as a bending between
two growth plates (Figure 1A arrow). Captured specimens were frozen in SuperAmp Lysis
Buffer (Miltenyi Biotec) and shipped to Miltenyi Biotec. mRNA was extracted and
transcribed into cDNA according to Miltenyi Biotec’s undisclosed procedure (SuperAmp
Miltenyi Biotec). The average length of cDNA products, measured and analyzed via the
Agilent 2100 Bioanalyzer platform and software (Agilent Technologies), ranged from 200–
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1000 bp, indicating the integrity of the cDNAs. The purified PCR products (250 ng) were
labeled with Cy3-dCTP and hybridized to an Agilent Whole Mouse Genome Oligo
Microarrays 4×44K for 17 hours at 65° according to Miltenyi Biotec’s undisclosed protocol.
Washing, staining and scanning of the microarrays were performed using the Agilent
Technologies equipment. Signal intensities from the single-experiment data were
normalized by dividing the intensity values by their median. NCBI GEO Accession number
GSE37287, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37287. Normalized
data were expressed as fold changes of a candidate gene in the interphalangeal interzone
sample compared to that obtained in chondrocytes using the Resolver (Rosetta Biosoftware).
Pathway analysis was performed using the PANTHER Classification System (Celera)
(Thomas et al., 2003). Lists of putative candidate genes with a fold change ± 2 and p-value
0.01 were compared to a reference list (Mus Musculus, NCBI) using a binomial test.
Microarray data will be accessible through the Gene Expression Omnibus (GEO) with the
final version of the manuscript.
Preparation of HGC-MCP-5/MC21 nanoparticles, implantation and ex-vivo limb cultures
HGC nanoparticles were prepared as previously reported (Li et al., 2010). Briefly, 25µg of
either recombinant mouse MCP-5 (R&D Systems) or MC-21 antibody (anti-CCR2)
(donated by M. Mack, Regensburg University) (Mack et al., 2001) were encapsulated into
250µg of HGC nanoparticles. Methylene Blue was added to the mixture to mark the
injection site. HGC-protein implantation was performed using a microinjection unit
(Picosprizer II) that allowed for precise localization of the injection and volume accuracy
(0.0015µl/shot) as previously described (Li et al., 2010). HCG-protein implants (joint site)
were performed in WT, NC or Tgfbr2Prx1KO by delivering either HGC-MC-21 (1.5 ng, 5-
shots, 0.3ng/shot) or increasing doses of HGC-MCP-5 (0.9ng, 1.5ng, 3ng and 6 ng). Limbs
were cultured in BGJb medium for 48 hours. HGC-protein implantation was performed
within the medial interphalangeal joint of 2nd, 3rd and 4th digit and the 5th uninjected digit of
the same limb was used as controls. The forming or presumptive interphalangeal joint was
identified as the bending between two adjacent growth plates.
RS-504393 in-vivo treatment
Pregnant NC females potentially generating Tgfbr2Prx1KO mice, were treated with 4mg/Kg/
day of RS-504393 (TOCRIS Bioscience), orally (in drinking water), starting at 11.5 days of
gestation, for a total of either 3 (E14.5) or 7 days (E18.5). After euthanasia of the mother,
limbs from either E14.5 or E18.5 embryos were dissected and prepared for histological
studies. Genotyping was used to confirm the mutant phenotype, RS-504393-treated NC
littermates and NC untreated mice were used as controls.
Isolation and culture of Jag+/TβRII+/PDGFR+ cells and TβRII+ cells
To obtain mesenchyme limb bud cells, the distal tips of E14.5 autopods from either WT or
Tgfbr2-GFP-β-GEO-BAC embryos were dissected and digested with dispase (1U/ml), as
previously reported (Spagnoli et al 2007). To obtain Jag+/TβRII+/PDGFR+ cells, WT
mesenchyme limb bud cells are subjected to immunoselection using biotinylated TβRII,
biotinylated PDGFRB (BAF532 and BAF1042, R&D Systems) and Jagged 1 (sc-6011,
Santa Cruz Biothechnolgy) antibodies. Biotinylation of Jagged1 antibody was performed
using Lightning-Link Biotin Conjugation Kit (Innova Biosciences) following
manufacturer’s protocol. Immunoselection was performed in a MACS magnetic system
(Miltenyi) as previously described (Longobardi et al 2005). Isolation of TβRII+ cells was
performed by FACS sorting (MoFlo, Beckman) mesenchyme limb bud cells from Tgfbr2-
GFP-β-GEO-BAC that contain GFP as gene reporters for Tgfbr2 (Spagnoli et al., 2007).
Micromass cultures were performed as previously reported (Spagnoli et al., 2007). Jag+/
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TβRII+/PDGFR+ or TβRII+ cells were treated with ±20ng/ml MCP-5 (for 3 days) or with
±20ng/ml TGF-β (for 18hours), respectively.
Histology, IHC and ISH
Dissected limbs from E14.5 to E18.5 embryos were fixed overnight in 4%PFA at 4°C,
paraffin embedded and sectioned at 5µm thickness. Hematoxylin staining was performed
following standard protocols.
For IHC, the Vectastain Elite ABC Kit (DakoCytomation) was used. The following primary
antibodies were used: anti-MCP-5 (G12) polyclonal (sc-33226, Santa Cruz) and anti-CCR-2
monoclonal (ab32144, Abcam). Histological sections were counterstained with
Hematoxylin.
ISH studies were performed as previously reported using DIG-labeled probes (Spagnoli et
al., 2007). The MCP-5 plasmid used to generate the MCP-5 probe was provided by Dr Karin
E. Peterson (Louisiana State University). After hybridization, probes were detected by
incubation with anti-DIG-AP antibody (Roche, Mannheim, Germany, dilution 1:5000).
Images were formatted without using any imaging enhancement.
Quantitative real-time PCR
mRNA from experiments using Jag+/TβRII+/PDGFR+ cells and TβRII+ cells was extracted
and reversed transcribed into cDNA by using µMACS mRNA Isolation and cDNA
Synthesis kit (Miltenyi Biotec). cDNAs (including from LCM) were analyzed by qRT-PCR
(MyIQ) using SYBR Green followed by Gene Expression Analysis Software (Bio-Rad).
Expression of genes of interest were normalized using either GAPDH or β-actin
expressions.
Statistics
Data are presented as mean ±SD. Statistical differences between groups were assessed by
one way ANOVA followed by Bonferroni’s Multiple Comparison test for all pairwise
multiple comparisons, or unpaired Student’s t-test (GraphPad Prism Software, San Diego,
CA, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1. MCP-5 is down-regulated in joint interzone cells compared to adjacent
chondrocytes
2. MCP-5 low expression in interzone is needed for joint and growth plate
development
3. TGF-β signaling in limbs is needed to establish a low MCP-5 interzone
expression
4. MCP-5 expression in chondrocytes contributes to growth plate development
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Figure 1. MCP-5 expression is down-regulated in the interzone of E14.5 NC embryos compared
to growth plate chondrocytes; this expression pattern is impaired in Tgfbr2Prx1KO
(A) Normal control (NC) and Tgfbr2Prx1KO sections before and after LCM of interzone cells
(interz) and adjacent growth plate chondrocytes (chondr). (B–C) Microarray and Panther
analyses of the cDNAs from LCM showing: (B) the differential regulation of the
“Inflammation mediated by chemokines and cytokines” signaling pathway in NC interzone
cells related to chondrocytes; (C) differential regulation of Mcp-5 and its receptor Ccr2 in
the interzone related to chondrocytes of both NC and Tgfbr2Prx1KO. (D) qRT-PCR analyses
of LCM samples showing expression of Mcp-5 in the NC interzone, as well as the
Tgfbr2Prx1KO presumptive interzone, compared to growth plate chondrocytes; experiments
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were repeated three times, gel lanes represent two representative experiments; data are
represented as mean ±SD, analyzed using one-way ANOVA (p<0.0001) followed by
Bonferroni’s multiple comparison test (*p<0.0001; **p<0.05). (E–F) Limb buds were
dissected from E14.5 NC and Tgfbr2Prx1KO embryos, embedded in paraffin and subjected to
(E) ISH and (F) IHC analyses using respectively MCP-5 probe and anti-MCP-5 antibody
(proximal side: right). Sections were obtained from at least 4 mutant and control embryos; at
least 6 sections for MCP-5 antibody and 8 sections for MCP-5 probe were analyzed. MCP-5
expression pattern was consistent in all the specimens analyzed. The expression pattern of
MCP-5 at different joint developmental time points (E12.5, E13.5, E14.5, E16.5 and E18.5)
is shown in Figure S1.
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Figure 2. Aberrant expression of Gdf5 and Collagen2 in E14.5 WT embryos after HGC-MCP-5
limb implantation and ex-vivo culture
(A–B) Recombinant MCP-5 was loaded in HGC-nanoparticle and the HGC-MCP-5
complex (MCP-5, 1.5 ng) was implanted in the 2nd, 3rd and 4th digit (highlighted by
Methylene Blue) of dissected E14.5 WT. Injected and uninjected (5th digit) limbs were
cultured for 48h, embedded in paraffin and subjected to (A) IHC analyses using MCP-5
antibody and (B) ISH studies using Gdf5 and Collagen2 (Col2) probes (proximal side:
right). Eight out of nine WT embryos implanted with HGC-MCP-5 showed an altered
phenotype, as described in the Results; analyses were performed in at least 3 sections for
each embryo and for each probe.
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Figure 3. Rescue of Tgfbr2Prx1KO joint phenotype by ex-vivo HGC-MC-21 limb implantation
and RS-504393 in-vivo treatment
(A) MC-21 antibody was loaded into HGC-nanoparticle and the resulting HGC-MC-21
complex (MC-21, 1.5 ng) was implanted in the interzone of dissected E14.5 NC and
Tgfbr2Prx1KO digits. Limbs were cultured for 48h, embedded in paraffin and subjected either
to hematoxylin staining or ISH analyses using Gdf-5, Col2 and Sox9 probes. (B–C)
RS-504393 treatments were started at E11.5 on pregnant females potentially carrying
Tgfbr2Prx1KO embryos and continued until either (B) E14.5 (3 days treatment) or (C) E18.5
(7 days of treatment); embryos were then harvested and genotyped. NC and Tgfbr2Prx1KO
limbs were dissected, embedded in paraffin and subjected either to hematoxylin staining or
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ISH analyses using Gdf-5 and Col2 probes (proximal side: left). All the 4 Tgfbr2Prx1KO
embryos implanted with HGC-MC-21 showed the phenotype described in the Results; for
the RS-504393 treatments, all the 4 Tgfbr2Prx1KO embryos treated for 3 days and all the 9
Tgfbr2Prx1KO embryos treated for 7 days showed the phenotype described in the Results;
analyses were performed in at least 3 sections for each embryo and for each probe. The
evaluation of CCR2 expression by IHC at different joint developmental time points (E12.5;
E13.5, E14.5 and E18.5) is shown in Figure S2.
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Figure 4. MCP-5 effect on joint interzone cells and relevance of TβRII signaling in regulating its
expression in vitro
(A-B-C) Jag+/TβRII+/PDGFR+ cells were isolated from E14.5 WT autopods. (A) mRNA
was collected after cell separation and subjected to RT-PCR for Collagen1 (Col1), Gdf5,
Wnt9a and Sulf1. (B–C) Micromass cultures of isolated Jag+/TβRII+/PDGFR+ were treated
±MCP-5 (20ng/ml) for 3 days and analyzed for morphology (B) and gene expression by RT-
PCR for Gdf5, Wnt9a, Sulf1 and Col2. (D) TβRII+ cells were FACS sorted from limb buds
cells isolated from Tgfbr2-GFP-β-GEO-BAC digits using GFP as selection marker for
TβRII expression. Micromass cultures of TβRII+ cells were treated ±TGF-β (20ng/ml) for
18h and analyzed for MCP-5 expression by qRT-PCR (n=3; mean ±SD; *p=0.0425 by one
tailed Student’s t-test). For RT-PCR experiments, gel lanes correspond to different
experiments that were repeated at least three times with similar results. The localization of
TβRII expressing cells within the interphalangeal joints is visualized in Figure S3.
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Figure 5. Aberrant expression of Ihh and Collagen10 in E14.5 WT embryos after ex-vivo HGC-
MCP-5 limb implantation
Recombinant MCP-5 was loaded in HGC-nanoparticle and the resulting HGC-MCP-5
complex (MCP-5, 1.5 ng) was implanted in the interzone of dissected E14.5 WT digits.
Limbs were cultured for 48h, embedded in paraffin and subjected to ISH analyses using Ihh
and Collagen10 (Col 10) probes (proximal side: left). Eight out of nine WT embryos
implanted with HGC-MCP-5 showed the altered phenotype; analyses were performed in at
least 3 sections for each embryo and for each probe. Figure S4 shows that in limb explants,
growth plate chondrocytes are capable to progress to hypertrophy after 2-day ex-vivo
culture.
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Figure 6. Blockade of CCR-2 signaling, both ex-vivo and in vivo, rescues the Tgfbr2Prx1KO
growth plate phenotype and advances ossification in NC growth plates
(A) MC-21 antibody was loaded in HGC-nanoparticle and the HGC-MC-21 complex
(MC-21, 1.5 ng) was implanted in the interzone of dissected E14.5 NC and Tgfbr2Prx1KO
digits. Limbs were cultured for 48h, embedded in paraffin and subjected to hematoxylin
staining and ISH analyses using Ihh, Col10 and Collagen1 (Col1) probes. (B) RS-504393
treatments were started at E11.5 on pregnant females potentially carrying Tgfbr2Prx1KO
embryos until E18.5 (7 days of treatment), when embryos were harvested and genotyped.
NC and Tgfbr2Prx1KO limbs were dissected, embedded in paraffin and subjected either to
hematoxylin staining or ISH analyses using Ihh, Col10 and Col1 probes (proximal side,
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left). All of the 4 Tgfbr2Prx1KO embryos implanted with HGC-MC-21 and all the 9
Tgfbr2Prx1KO embryos treated with RS-504393 showed the phenotype described in the
Results; analyses were performed in at least 3 sections for each embryo and for each probe.
The evaluation of CCR2 expression by IHC at different joint developmental time points
(E12.5; E13.5, E14.5 and E18.5) is shown in Figure S2.
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Figure 7. A model for the TβRII+/MCP-5 axis during joint and growth plate development
(A, Wild-type, WT, mice) TβRII down-regulates MCP-5 expression in the interzone,
allowing expression of key joint markers (such as Gdf5) while inhibiting Collagen2
expression. In the growth plate, the down-regulation of interzone MCP-5 (TβRII-dependent)
signals the correct Ihh expression pattern, promoting chondrocyte maturation, while MCP-5
within the growth plate (TβRII-independent) inhibits chondrocyte terminal differentiation.
The balance between these two opposite signals is necessary for a proper endochondral
ossification process. (B, Tgfbr2Prx1KO mutants) Lack of the TβRII signaling leads to up-
regulation of interzone MCP-5 with consequent lack of joint formation. Furthermore,
MCP-5 abnormal up-regulation in the interzone does not counteract the MCP-5 inhibitory
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coming from within the growth plate and enhances Ihh altered distribution with consequent
impairment in chondrocyte hypertrophy and ossification.
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